**1. History**

Lillehei was the first to report an experimental isolated intestinal canine model in 1959 and Starzl reported the first multivisceral experimental canine model in 1960 [1, 2]. The first attempt in humans has been attributed to Deterling in Boston in 1964 [unpublished], whereas the first official report of human intestinal transplant was made by Lillehei in 1967 [1]. It should be noted that the first successful series were reported in the 1990s, coinciding with the introduction of more effective immunosuppression. The first attempts of intestinal transplantation (ITx) in the 1970s were largely disappointing because of high incidence of rejection of small bowel allografts, sepsis and technical complications [3]. The introduction of tacrolimus [4] revolutionized interest in ITx. The superior clinical outcomes from tacrolimus across a

© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

variety of organ transplantation compared with cyclosporine set the momentum for ITx as a life-changing therapy for patients with irreversible intestinal failure (IF) [5, 6].

Short bowel syndrome caused by surgical removal is the leading cause of IF (68%). As an early alternative to transplantation or total parenteral nutrition (TPN) for patients with short bowel syndrome, surgical bowel lengthening without transplant may be attempted. This requires the serial transverse enteroplasty (STEP) or longitudinal intestinal lengthening and tailoring (LILT) procedures. STEP and LILT are particularly successful in patients with decreased transit times and dilated bowel. These procedures lengthen the small bowel while keeping the total surface area the same. Bowel is either split lengthwise or cut obliquely at multiple points. This will lengthen the bowel and shrink the luminal diameter [12]. If successful, this may reduce the amount of TPN required, or negate its use altogether. If patients are not acceptable candidates for STEP or LILT, sometimes a reversal of small bowel direction may effectively increase transit times. If none of these operations are successful, the

Intestinal Transplantation

291

http://dx.doi.org/10.5772/intechopen.74825

Currently, ITx has been mainly performed in patients who developed life-threatening complications attributed to IF and/or long-term TPN. In 2000, Medicare defined failure of TPN as impending or overt liver failure (elevated serum bilirubin and/or liver enzymes, splenomegaly, thrombocytopenia, gastroesophageal varices, coagulopathy, stomal bleeding, hepatic fibrosis or cirrhosis), thrombosis of two or more central veins, frequent and severe central venous catheter (CVC)-related sepsis and frequent severe dehydration [13]. In addition, other conditions associated with early death despite optimal TPN, such as congenital mucosal disorders and ultra-short bowel syndrome, are also included as per American Society of

The European guidelines recommend TPN as primary treatment for patients with IF, with early referral to specialist centers for optimal rehabilitative therapy and timely assessment of suitability for ITx. It recommends assessment for candidacy for transplantation for the presence of one or more indications parallel to American guidelines (failure of TPN, high risk of death attributable to underlying disease and IF with high morbidity or low acceptance of TPN) resulting in rates of transplant of 62, 26 and 12%, respectively [15]. Because of a statistically significant increased risk of death on TPN from liver failure due to IFALD and invasive intra-abdominal desmoids, direct referral for ITx should be considered [16]. IFALD is partly caused by omega-6 fatty acids in TPN formulas, which can be synthesized into inflammatory molecules. IFALD can range from steatohepatitis, cholestasis or hepatic fibrosis to end-stage liver disease. Children are more likely to have cholestatic liver disease than steatohepatitis [17]. Severe liver injury has been reported in as many as 50% of patients with IF who receive TPN for longer than 5 years; this is typically fatal. If patients have life-threatening infections, IFALD, or lose their venous access, 1-year mortality is 70% without ITx [18]. Conversely, patients with CVC-related complications or ultra-short bowel syndrome did not have an increased risk of death on TPN and no patients considered to be an ITx candidate with poor quality of life (QoL) or chronic dehydration actually died while remaining on TPN. This notable finding forms the basis of non-indications in previous European guidelines [19]. Despite very limited evidence exploring the role of quality of life (QoL) as an indicator for ITx, this holistic aspect may also be factored in the

standard of care is TPN.

Transplantation guidelines [14].

decision-making process [20] (**Table 2**).

Over the past 30 years, there has been a gradual increase in ITx cases, with nearly 2900 ITx cases performed worldwide, although there has been a decline in recent years [7]. This change could be attributed to the formation of specialized IF units to prevent and manage intestinal failure-associated liver disease (IFALD) [8]. Other possible factors include: inadequate reimbursement rates below the cost of performing the transplant; the extensive infrastructure demands required to address the frequent social problems of IF patients; concern over the narrow risk-benefit ratio for ITx in an era of improving outcomes with long-term total parenteral nutrition (TPN) for selected diseases [9] and/or the limited availability of experienced personnel to fill key positions. Finally, some transplant centers may be more willing to judiciously offer isolated liver transplants to patients with the short bowel syndrome and IFALD who have the potential for further intestinal adaptation [10, 11].
